ASO Author Reflections: Future Prospects of Neoadjuvant Chemotherapy for Gastric Cancer

  • Masayuki KanoEmail author
  • Hisahiro Matsubara
ASO Author Reflections



The author reports no conflicts of interest.


  1. 1.
    Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.CrossRefGoogle Scholar
  2. 2.
    Iwasaki Y, Terashima M, Mizusawa J, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501). J Clin Oncol. 2018;36(15 suppl):4046CrossRefGoogle Scholar
  3. 3.
    Kodera Y, Yoshida K, Kochi M, et al. A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial). J Clin Oncol. 2018;36(15 suppl):4007CrossRefGoogle Scholar
  4. 4.
    Kano M, Hayano K, Hayashi H, et al. Survival benefit of neoadjuvant chemotherapy with S-1 plus docetaxel for locally advanced gastric cancer: a propensity score-matched analysis. Ann Surg Oncol. 2019;26:1805–13.CrossRefGoogle Scholar
  5. 5.
    Yamada Y, Boku N, Mizusawa J, et al. Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013). J Clin Oncol. 2018;36(15 suppl):4009CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Frontier SurgeryChiba UniversityChibaJapan

Personalised recommendations